razoxane has been researched along with Cardiovascular Stroke in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Li, K; Ng, PC; Pong, NH; Shen, J; Sung, RY; Xiang, P; Zhou, L | 1 |
| Filipský, T; Holečková, M; Hrdina, R; Macáková, K; Mladěnka, P; Palicka, V; Semecký, V; Vávrová, J; Zatloukalová, L | 1 |
| Boudíková, A; Dabrowská, L; Geršl, V; Kolář, F; Mandíková, P; Mikšík, I; Mráz, J; Neckář, J; Popelová, O; Stěrba, M | 1 |
3 other study(ies) available for razoxane and Cardiovascular Stroke
| Article | Year |
|---|---|
Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Cell Count; Bone Marrow Cells; Capillaries; Cardiotonic Agents; Disease Models, Animal; Down-Regulation; Echocardiography; Endothelial Cells; Male; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Razoxane; Stem Cells; Stroke Volume | 2011 |
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity.
Topics: Animals; Calcium; Cardiotonic Agents; Disease Models, Animal; Hemodynamics; Iron; Iron Chelating Agents; Isoproterenol; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Razoxane | 2012 |
Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Perfusion; Rats; Rats, Wistar; Razoxane; Reactive Oxygen Species; Treatment Outcome | 2012 |